These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 4347003)

  • 1. [Short term toxicity and efficacy of 4 different cytosine-arabinoside regimens in 40 cases of human solid tumors].
    Israel L; Hamel C; Guibout P; Kreis B
    Sem Hop; 1972 Nov; 48(47):3093-7. PubMed ID: 4347003
    [No Abstract]   [Full Text] [Related]  

  • 2. A clinical evaluation of dose and schedule of administration of cytosine arabinoside (NSC 63878).
    Burke PJ; Serpick AA; Carbone PP; Tarr N
    Cancer Res; 1968 Feb; 28(2):274-9. PubMed ID: 4868015
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878).
    Frei E; Bickers JN; Hewlett JS; Lane M; Leary WV; Talley RW
    Cancer Res; 1969 Jul; 29(7):1325-32. PubMed ID: 5799155
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial.
    Stevens DA; Jordan GW; Waddell TF; Merigan TC
    N Engl J Med; 1973 Oct; 289(17):873-8. PubMed ID: 4354007
    [No Abstract]   [Full Text] [Related]  

  • 5. A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC63878).
    Burke PJ; Owens AH; Colsky J; Shnider BI; Edmonson JH; Schilling A; Brodovsky HS; Wallace HJ; Hall TC
    Cancer Res; 1970 May; 30(5):1512-5. PubMed ID: 5426952
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytosine arabinoside (NSC 63878) toxicity and antitumor acitivity in human solid tumors.
    Davis HL; Rochlin DB; Weiss AJ; Wilson WL; Andrews NC; Madden R; Sedransk N
    Oncology; 1974; 29(3):190-200. PubMed ID: 4412696
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytosine arabinoside (NSC-63878)--clinical brochure.
    Livingston RB; Carter SK
    Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
    [No Abstract]   [Full Text] [Related]  

  • 8. [Combined application of drugs in cancer chemotherapy with special reference to the combination of mitomycin C, 5-fluorouracil, and cytosine arabinoside].
    Nakao I; Furue H; Furukawa K; Kanko T; Harashima S
    Gan No Rinsho; 1972 Feb; 18(2):138-43. PubMed ID: 5063156
    [No Abstract]   [Full Text] [Related]  

  • 9. [Herpesvirus diseases in children with acute leukosis. Treatment with cytosine-arabinoside].
    Gunkel U; Kropp H
    Fortschr Med; 1974 Mar; 92(9):393-5. PubMed ID: 4362176
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical pharmacology and human antitumor activity of cytosine arabinoside.
    Talley RW; O'Bryan RM; Tucker WG; Loo RV
    Cancer; 1967 May; 20(5):809-16. PubMed ID: 6071587
    [No Abstract]   [Full Text] [Related]  

  • 11. Failure of cytosine arabinoside in treating smallpox. A double-blind study.
    Dennis DT; Doberstyn EB; Awoke S; Royer GL; Renis HE
    Lancet; 1974 Aug; 2(7877):377-9. PubMed ID: 4136735
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside.
    Cendrowski W
    Acta Neurol Belg; 1973; 73(4):209-19. PubMed ID: 4770124
    [No Abstract]   [Full Text] [Related]  

  • 13. [Letter: Cytosine arabinoside and generalized zoster].
    Huis J; Van Vaerenbergh PM; Kindt R
    Nouv Presse Med; 1973 Nov; 2(41):2752. PubMed ID: 4589880
    [No Abstract]   [Full Text] [Related]  

  • 14. Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro.
    Kessel D; Hall TC; Rosenthal D
    Cancer Res; 1969 Feb; 29(2):459-63. PubMed ID: 5250069
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating carrier erythrocytes: slow-release vehicle for an antileukemic drug, cytosine arabinoside.
    DeLoach JR; Barton C
    Am J Vet Res; 1982 Dec; 43(12):2210-2. PubMed ID: 7165167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.
    Karbasian-Esfahani M; Wiernik PH; Novik Y; Paietta E; Dutcher JP
    Cancer; 2004 Sep; 101(6):1414-9. PubMed ID: 15368329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies with tubercidin administered after absorption into human erythrocytes.
    Grage TB; Rochlin DB; Weiss AJ; Wilson WL
    Cancer Res; 1970 Jan; 30(1):79-81. PubMed ID: 4985935
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 19. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
    Estlin EJ; Yule SM; Lowis SP
    Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biochemical basis of the treatment of leukemia with cytosine-arabinoside].
    Wilmanns H
    Schweiz Med Wochenschr; 1970 Feb; 100(7):323-5. PubMed ID: 5413922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.